

Jeffrey L Cummings

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1889933/jeffrey-l-cummings-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

350
papers

47,336
citations

89
h-index

216
g-index

389
ext. papers

57,693
ext. citations

7
avg, IF

7.74
L-index

#	Paper	IF	Citations
350	Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials.. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2022 , 9, 241-246	3.8	
349	Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 7	9	3
348	Pimavanserin and dementia-related psychosis.. <i>Lancet Neurology, The</i> , 2022 , 21, 114-115	24.1	
347	Aducanumab: Appropriate Use Recommendations Update.. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2022 , 9, 221-230	3.8	2
346	Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem 2022 , 123-134		
345	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022 , appineuropsych21050135	2.7	1
344	Financing Alzheimer's Disease Drug Development 2022 , 465-479		0
343	ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development 2022 , 177-189		
342	The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program 2022 , 309-318		
341	Alzheimer's Disease Drug Development: A Research and Development Ecosystem 2022 , 1-24		1
340	Globalization of Alzheimer's Disease Clinical Trials 2022 , 275-280		
339	The Use and Development of Clinical Measures of Alzheimer's Disease Trials 2022 , 281-291		
338	Introduction to Venture Capital in Alzheimer's Disease Drug Development 2022 , 524-532		
337	The Harrington Discovery Institute and Alzheimer's Disease Drug Development 2022 , 45-53		
336	The Importance of Phase 2 in Drug Development for Alzheimer's Disease 2022 , 150-161		
335	Artificial Intelligence in Alzheimer's Drug Discovery 2022 , 62-72		
334	Role of Animal Models in Alzheimer's Disease Drug Development 2022 , 73-94		

333	Institutional Review Boards and Oversight of Alzheimer’s Disease Trials 2022 , 429-436		
332	Alzheimer’s Disease Clinical Trial Study Partners 2022 , 333-342		
331	Drug Development for Alzheimer’s Disease: An Historical Perspective 2022 , 25-33		
330	Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development 2022 , 480-485		
329	Alzheimer’s Disease Neuroimaging Initiative 2022 , 455-464		
328	Best Practices for Clinical Trials during COVID-19 2022 , 354-360		
327	Alzheimer’s Disease Drug Development in Pharmaceutical Companies 2022 , 162-169		
326	Development of Fluid Biomarkers for Alzheimer’s Disease 2022 , 361-374		
325	Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials 2022 , 232-248		
324	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease.. <i>Alzheimer’s Research and Therapy</i> , 2022 , 14, 54	9	2
323	Alzheimer’s disease drug development pipeline: 2022.. <i>Alzheimer’s and Dementia: Translational Research and Clinical Interventions</i> , 2022 , 8, e12295	6	7
322	Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 804168	5	
321	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease.. <i>Nature Aging</i> , 2021 , 1, 1175-1188		13
320	The Alzheimer’s disease drug development landscape. <i>Alzheimer’s Research and Therapy</i> , 2021 , 13, 186	9	7
319	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2021 ,	13.5	17
318	Development and assessment of a brief screening tool for psychosis in dementia.. <i>Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12254	5.2	
317	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021 , 96, 848-863	6.5	30
316	A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. <i>Alzheimer’s Research and Therapy</i> , 2021 , 13, 62	9	28

315	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021 , 96, 944-954	6.5	5
314	International Psychogeriatric Association (IPA) consensus for defining psychosis in major and mild neurocognitive disorders. <i>International Psychogeriatrics</i> , 2021 , 1-5	3.4	0
313	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 80	9	92
312	Alzheimer's disease. <i>Lancet, The</i> , 2021 , 397, 1577-1590	40	245
311	Building brain capital. <i>Neuron</i> , 2021 , 109, 1430-1432	13.9	0
310	Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1649-1662	4.3	2
309	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
308	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 98	9	57
307	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology, The</i> , 2021 , 20, 484-496	24.1	86
306	Brain Health Living Labs. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 698-703	6.5	1
305	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021 , 385, 309-319	19.2	18
304	Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index. <i>Frontiers in Neurology</i> , 2021 , 12, 605318	4.1	0
303	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021 , 56, 70-85	2.3	2
302	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 375-383	6.5	11
301	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021 , 33, 3-13	2.7	5
300	Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". <i>Alzheimer's and Dementia</i> , 2021 , 17, 702-703	1.2	10
299	Alzheimer's disease drug development pipeline: 2021. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12179	6	53
298	Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12106	6	4

297	New approaches to symptomatic treatments for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021 , 16, 2	19	35
296	Who funds Alzheimer's disease drug development?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12185	6	2
295	Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021 , 8, 398-410	3.8	26
294	AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 24	9	14
293	Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. <i>Genome Research</i> , 2021 , 31, 1900-1912	9.7	13
292	Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease. <i>Neurology</i> , 2021 , 97, 543-544	6.5	11
291	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021 , 17, 580-589	15	25
290	Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. <i>Neurology and Therapy</i> , 2021 , 10, 941-953	4.6	4
289	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 1703-1715	4.3	3
288	Why aducanumab is important. <i>Nature Medicine</i> , 2021 , 27, 1498	50.5	4
287	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63
286	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 136	9	1
285	The costs of developing treatments for Alzheimer's disease: A retrospective exploration. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	3
284	Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12136	6	1
283	Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401). <i>Touch Reviews in Neurology</i> , 2021 , 17, 70		
282	Development and assessment of a brief screening tool for psychosis in dementia.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 8, e057766	1.2	
281	Affective Computing for Late-Life Mood and Cognitive Disorders.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 782183	9	0
280	Pioglitazone reduces the incidence of Alzheimer's disease: From genetics to population-based validation.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e051950	1.2	

279	Multimodal single-cell/nucleus RNA-sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e051952	1.2	
278	Key developmental milestones for tau therapeutics. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044896	1.2	
277	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12098	5.2	1
276	A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 547-557	4.3	10
275	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020 , 49, 22-37	2.6	4
274	An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home. <i>Frontiers in Psychiatry</i> , 2020 , 11, 173	5	5
273	Brain health INnovation Diplomacy: a model binding diverse disciplines to manage the promise and perils of technological innovation. <i>International Psychogeriatrics</i> , 2020 , 32, 955-979	3.4	14
272	The Neuropsychiatric Inventory: Development and Applications. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020 , 33, 73-84	3.8	23
271	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. <i>Journal of Personalized Medicine</i> , 2020 , 11,	3.6	8
270	Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12115	6	0
269	The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs. <i>Journal of Prevention of Alzheimer's Disease</i> , 2020 , 7, 288-290	3.8	0
268	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. <i>Neurology</i> , 2020 , 94, e774-e784	6.5	13
267	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1143-1156	4.3	17
266	Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 1256-1269	6.5	15
265	β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
264	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1483-1492	1.2	20
263	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
262	Alzheimer's disease drug development pipeline: 2020. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12050	6	161

261	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. <i>Medicinal Research Reviews</i> , 2020 , 40, 2386-2426	14.4	25
260	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. <i>Brain</i> , 2020 , 143, 3816-3826	11.2	16
259	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020 , 16, 661-673	15	44
258	Repurposed agents in the Alzheimer's disease drug development pipeline. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 98	9	18
257	Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 383-400	6.5	31
256	Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020 , 33, 124-134	3.8	2
255	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 76	9	93
254	Sex Moderates Amyloid and Apolipoprotein E Effects on Default Mode Network Connectivity at Rest. <i>Frontiers in Neurology</i> , 2019 , 10, 900	4.1	9
253	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019 , 217, 72-83	4.9	27
252	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 779-794	4.3	163
251	Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 953-961	4.3	16
250	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 164-174	6	9
249	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 1408-1420	59.2	268
248	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 68	9	22
247	Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. <i>Current Psychiatry Reports</i> , 2019 , 21, 79	9.1	20
246	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 73	9	14
245	A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 231-240	6	9
244	Alzheimer's disease drug development pipeline: 2019. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 272-293	6	378

243	Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019 , 6, 157-163	3.8	39
242	Clinical drug development for dementia with Lewy bodies: past and present. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 951-965	5.9	13
241	The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. <i>Alzheimer's and Dementia</i> , 2019 , 15, 172-178	1.2	59
240	The Role of Biomarkers in Alzheimer's Disease Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1118, 29-61	3.6	40
239	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 109	9	9
238	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 303-313	4.3	6
237	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S3-S22	4.3	74
236	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018 , 130, 331-365	10.2	60
235	Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurology</i> , 2018 , 17, 213-222	24.1	99
234	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 130-142	27.4	92
233	Alzheimer's disease drug development pipeline: 2018. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 195-214	6	359
232	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018 , 378, 1691-1703	59.2	370
231	ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. <i>Neurology</i> , 2018 , 90, e1889-e1897	6.5	123
230	Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 256-271	6	6
229	Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. <i>Experimental Gerontology</i> , 2018 , 111, 118-121	4.5	28
228	Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 173-181	6	30
227	Statistical advances in clinical trials and clinical research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 366-371	6	15
226	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018 , 90, 74-82	6.5	10

225	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , 2018 , 11, 147-152	4.9	149
224	Pimavanserin: Potential Treatment For Dementia-Related Psychosis. <i>Journal of Prevention of Alzheimer's Disease</i> , 2018 , 5, 253-258	3.8	31
223	Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 1223-1234	4.3	20
222	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018 , 136, 821-853	14.3	236
221	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 116	9	11
220	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 102	9	13
219	Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 79-89	4.3	11
218	The price of progress: Funding and financing Alzheimer's disease drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018 , 4, 330-343	6	33
217	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 929-938	4.3	182
216	Alzheimer's disease drug development pipeline: 2017. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 367-384	6	256
215	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 387-393	4.3	8
214	Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 1-9	6	9
213	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 60	9	197
212	Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 72	9	29
211	Disease modification and Neuroprotection in neurodegenerative disorders. <i>Translational Neurodegeneration</i> , 2017 , 6, 25	10.3	38
210	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1131-1139	4.3	27
209	Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. <i>Journal of Prevention of Alzheimer's Disease</i> , 2017 , 4, 149-156	3.8	27
208	Drug Development in Alzheimer's Disease: The Role of Default Mode Network Assessment in Phase II. <i>US Neurology</i> , 2017 , 13, 67	0.3	7

207	Atypical Alzheimer's Disease, Mixed Dementia, and Amyloid Angiopathy 2017 , 39-47		
206	Incidence of dementia and subtypes: A cohort study in four regions in China. <i>Alzheimer's and Dementia</i> , 2016 , 12, 262-71	1.2	36
205	Alzheimer's drug-development pipeline: 2016. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016 , 2, 222-232	6	76
204	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 39	9	234
203	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 4	9	104
202	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
201	Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1166-7	27.4	2
200	Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. <i>CNS Neuroscience and Therapeutics</i> , 2016 , 22, 159-66	6.8	69
199	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 993-9	5.5	82
198	Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016 , 6, 214-21	2.5	4
197	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , 2015 , 138, 1036-45	11.2	54
196	Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. <i>International Journal of Clinical Practice</i> , 2015 , 69, 518-30	2.9	11
195	Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 159-73	3.8	34
194	Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 9	9	5
193	Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1242-54	27.4	118
192	Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 39	9	17
191	Alzheimer's disease progression by geographical region in a clinical trial setting. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 43	9	20
190	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 455-61	1.2	7

189	Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. <i>Journal of Alzheimer's Disease</i> , 2015 , 43, 949-55	4.3	55
188	A practical algorithm for managing Alzheimer's disease: what, when, and why?. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 307-23	5.3	52
187	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15056	51.1	755
186	Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440). <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, S164-S165	6.5	5
185	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 205-14	4.3	39
184	Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. <i>Journal of the American Geriatrics Society</i> , 2015 , 63, 1448-52	5.6	18
183	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. <i>Frontiers in Neurology</i> , 2015 , 6, 186	4.1	19
182	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. <i>Current Alzheimer Research</i> , 2015 , 12, 712-22	3	104
181	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. <i>International Psychogeriatrics</i> , 2015 , 27, 7-17	3.4	181
180	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014 , 383, 533-40	4.0	519
179	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
178	Overcoming obstacles to repurposing for neurodegenerative disease. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 512-8	5.3	34
177	Alzheimer's disease drug-development pipeline: few candidates, frequent failures. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 37	9	1023
176	Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. <i>Translational Neurodegeneration</i> , 2014 , 3, 12	10.3	13
175	Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 335-43	2.5	25
174	The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive. <i>Journal of Alzheimer's Disease</i> , 2014 , 38, 103-9	4.3	6
173	Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 161-5	3.8	21
172	The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 509-16	2.5	39

171	Challenges and Opportunities to Conduct Global Alzheimer's Disease Clinical Trials 2014 , 61-75		
170	Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. <i>International Psychogeriatrics</i> , 2014 , 26, 1871-4	3.4	4
169	The "Alzheimer's type" profile of semantic clustering in amnesic mild cognitive impairment. <i>Journal of the International Neuropsychological Society</i> , 2014 , 20, 402-12	3.1	12
168	Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 37, 315-26	2.6	52
167	Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 224-33	2.6	15
166	Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. <i>BMC Geriatrics</i> , 2013 , 13, 56	4.1	23
165	Alzheimer's disease drug development: translational neuroscience strategies. <i>CNS Spectrums</i> , 2013 , 18, 128-38	1.8	22
164	The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. <i>Neurobiology of Aging</i> , 2013 , 34, 1913-20 ^{5,6}	5.6	39
163	Alzheimer's disease biomarkers: correspondence between human studies and animal models. <i>Neurobiology of Disease</i> , 2013 , 56, 116-30	7.5	15
162	Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. <i>Neurobiology of Aging</i> , 2013 , 34, 169-83	5.6	58
161	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , 2013 , 34, 62-72	5.6	40
160	Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. <i>American Journal of Geriatric Psychiatry</i> , 2013 , 21, 607-22	6.5	33
159	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). <i>Alzheimer's and Dementia</i> , 2013 , 9, 189-98	1.2	42
158	Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 295-9	3.6	49
157	Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013 , 9, 176-88	1.2	45
156	The Dementia and Disability Project in Thai Elderly: rationale, design, methodology and early results. <i>BMC Neurology</i> , 2013 , 13, 3	3.1	8
155	High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. <i>CNS Neuroscience and Therapeutics</i> , 2013 , 19, 294-301	6.8	44
154	International Work Group criteria for the diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 363-8	7	55

153	Clinical trials in predementia stages of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 439-57	7	37
152	A review: treatment of Alzheimer's disease discovered in repurposed agents. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 35, 1-22	2.6	59
151	Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013 , 28, 583-91	2.5	12
150	Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. <i>Alzheimer Disease and Associated Disorders</i> , 2013 , 27, 174-81	2.5	17
149	Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. <i>International Psychogeriatrics</i> , 2013 , 25, 431-8	3.4	10
148	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013 , 25, 707-19	3.4	37
147	The utility of the new research diagnostic criteria for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013 , 25, 175-7	3.4	8
146	Alzheimer's disease biomarkers in animal models: closing the translational gap. <i>American Journal of Neurodegenerative Disease</i> , 2013 , 2, 108-20	2.5	13
145	Discovering new treatments for Alzheimer's disease by repurposing approved medications. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 2306-27	3	48
144	Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2012 , 27, 421-32	2.5	20
143	Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012 , 2, a006395	5.4	48
142	Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm ²) in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 33, 341-53	2.6	65
141	Reviewing the role of donepezil in the treatment of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2012 , 9, 773-81	3	20
140	Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 33, 1-5	2.6	34
139	Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. <i>Archives of Neurology</i> , 2012 , 69, 901-5		53
138	Advances in designs for Alzheimer's disease clinical trials. <i>American Journal of Neurodegenerative Disease</i> , 2012 , 1, 205-16	2.5	22
137	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , 2011 , 43, 436-41	36.3	1367
136	Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. <i>BMC Neurology</i> , 2011 , 11, 21	3.1	43

135	Alzheimer's disease clinical trials: changing the paradigm. <i>Current Psychiatry Reports</i> , 2011 , 13, 437-42	9.1	11
134	Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 150-7	3.9	39
133	Globalization of Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , 2011 , 3, 24	9	23
132	Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. <i>Archives of General Psychiatry</i> , 2011 , 68, 853-61		146
131	The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. <i>Brain</i> , 2011 , 134, 3146-66	11.2	144
130	Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 375-88	4.3	2
129	Management of behavioral problems in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2010 , 22, 346-72	3.4	251
128	What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?. <i>Biological Psychiatry</i> , 2010 , 68, 876-8	7.9	54
127	Integrating ADNI results into Alzheimer's disease drug development programs. <i>Neurobiology of Aging</i> , 2010 , 31, 1481-92	5.6	44
126	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , 2010 , 31, 1284-303	5.6	114
125	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. <i>NeuroImage</i> , 2010 , 51, 488-99	7.9	71
124	Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. <i>International Psychogeriatrics</i> , 2010 , 22, 973-83	3.4	33
123	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 509-16	4.3	306
122	Commentary on: L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. <i>CNS Spectrums</i> , 2010 , 15, 7	1.8	1
121	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. <i>Human Brain Mapping</i> , 2010 , 31, 786-97	5.9	79
120	Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. <i>Annals of Neurology</i> , 2010 , 68, 693-702	9.4	202
119	Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. <i>Archives of Neurology</i> , 2009 , 66, 888-93		89
118	Management of agitation and aggression associated with Alzheimer disease. <i>Nature Reviews Neurology</i> , 2009 , 5, 245-55	15	260

117	Defining and labeling disease-modifying treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009 , 5, 406-18	1.2	41
116	The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. <i>Alzheimer Disease and Associated Disorders</i> , 2009 , 23, 91-101	2.5	525
115	Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 115-26	2.6	250
114	Optimizing phase II of drug development for disease-modifying compounds. <i>Alzheimer's and Dementia</i> , 2008 , 4, S15-20	1.2	18
113	Controversies in Alzheimer's disease drug development. <i>International Review of Psychiatry</i> , 2008 , 20, 389-95	3.6	17
112	Integrating symptomatic- and disease-modifying treatments. <i>CNS Spectrums</i> , 2008 , 13, 28-30	1.8	3
111	Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 889-98	4.6	166
110	Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. <i>CNS Spectrums</i> , 2008 , 13, 4-5	1.8	6
109	A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 456-67	3.9	219
108	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1689-707; quiz 1837	7	1968
107	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. <i>Lancet Neurology</i> , 2007 , 6, 501-12	24.1	260
106	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , 2007 , 6, 734-46	24.1	3067
105	Disease-modifying therapies for Alzheimer disease: challenges to early intervention. <i>Neurology</i> , 2007 , 69, 1622-34	6.5	217
104	Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. <i>Brain</i> , 2007 , 130, 1767-76	11.2	195
103	Positron emission tomography metabolic correlates of apathy in Alzheimer disease. <i>Archives of Neurology</i> , 2007 , 64, 1015-20		158
102	Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. <i>Neurology</i> , 2007 , 68, 1356-63	6.5	162
101	Clinical Trials in Dementia. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007 , 2, 39-78		
100	Progress in Neurotherapeutics and Neuropsychopharmacology 2007. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007 , 2, 1-12		

99	Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 253-9	2.6	130
98	Structural correlates of apathy in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 91-7	2.6	120
97	Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. <i>Reviews in Neurological Diseases</i> , 2007 , 4, 57-62		15
96	Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. <i>Psychopharmacology Bulletin</i> , 2007 , 40, 89-98	0.9	6
95	Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. <i>Archives of Neurology</i> , 2006 , 63, 693-9		391
94	Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. <i>Neurology</i> , 2006 , 67, 57-63	6.5	174
93	Neuropathologic correlates of apathy in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 21, 144-7	2.6	95
92	Serotonin 1A receptors in the living brain of Alzheimer's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 702-7	11.5	196
91	Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. <i>American Journal of Geriatric Psychiatry</i> , 2006 , 14, 605-12	6.5	106
90	ADCS Prevention Instrument Project: overview and initial results. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, S109-23	2.5	53
89	Neuropathologic correlates of activities of daily living in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, 56-9	2.5	39
88	The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, 210-6	2.5	568
87	ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. <i>Alzheimer Disease and Associated Disorders</i> , 2006 , 20, S147-51	2.5	11
86	Defining and diagnosing involuntary emotional expression disorder. <i>CNS Spectrums</i> , 2006 , 11, 1-7	1.8	152
85	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 64-74	64.1	34
84	Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 469-474	6.5	164
83	Clinical evaluation as a biomarker for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2005 , 8, 327-374.3		11
82	Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease. <i>International Psychogeriatrics</i> , 2005 , 17, 81-90	3.4	30

81	The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. <i>Journal of the American Geriatrics Society</i> , 2005 , 53, 695-9	5.6	11162
80	Behavioural changes and psychological symptoms in dementia disorders. <i>Lancet Neurology, The</i> , 2005 , 4, 735-42	24.1	164
79	Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. <i>Archives of Neurology</i> , 2005 , 62, 721-8		104
78	Neuropsychiatric symptoms and quality of life in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 469-74	6.5	97
77	Executive dysfunction in Alzheimer disease. <i>Archives of Neurology</i> , 2004 , 61, 556-60		144
76	Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. <i>Archives of Neurology</i> , 2004 , 61, 1249-53		107
75	Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. <i>American Journal of Psychiatry</i> , 2004 , 161, 532-8	11.9	120
74	Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 32-5	3.8	54
73	Fluctuations in cognitive function in dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2004 , 3, 266	24.1	13
72	Alzheimer's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 56-67	59.2	1096
71	Dementia with lewy bodies: molecular pathogenesis and implications for classification. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004 , 17, 112-9	3.8	31
70	Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. <i>Alzheimer Disease and Associated Disorders</i> , 2004 , 18, 17-21	2.5	188
69	Regression to the mean: implications for clinical trials of psychotropic agents in dementia. <i>Current Alzheimer Research</i> , 2004 , 1, 323-8	3	11
68	Treatment of Alzheimer's disease: current and future therapeutic approaches. <i>Reviews in Neurological Diseases</i> , 2004 , 1, 60-9		55
67	Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 99-106	4.3	16
66	A new measurement of activities of daily living for Thai elderly with dementia. <i>International Psychogeriatrics</i> , 2003 , 15, 135-48	3.4	15
65	Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. <i>American Journal of Psychiatry</i> , 2003 , 160, 341-9	11.9	140
64	Toward a molecular neuropsychiatry of neurodegenerative diseases. <i>Annals of Neurology</i> , 2003 , 54, 147-54		80

63	The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. <i>Journal of Sleep Research</i> , 2003 , 12, 331-7	5.8	113
62	Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. <i>Molecular Genetics and Metabolism</i> , 2003 , 80, 350-5	3.7	43
61	Alzheimer's disease: from molecular biology to neuropsychiatry. <i>Seminars in Clinical Neuropsychiatry</i> , 2003 , 8, 31-6		10
60	Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. <i>American Journal of Geriatric Psychiatry</i> , 2003 , 11, 131-45	6.5	33
59	Alzheimer disease. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 2335-8	27.4	287
58	Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002 , 13, 67-73	2.6	86
57	Prevalence and impact of medical comorbidity in Alzheimer's disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2002 , 57, M173-7	6.4	165
56	A videotape-based training method for improving the detection of depression in residents of long-term care facilities. <i>Gerontologist, The</i> , 2002 , 42, 114-21	5	89
55	Apathy and executive function in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2002 , 8, 373-81	3.1	105
54	Provisional Diagnostic Criteria for Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2002 , 10, 125-128	6.5	234
53	Guidelines for managing Alzheimer's disease: part I. Assessment. <i>American Family Physician</i> , 2002 , 65, 2263-72	1.3	57
52	Guidelines for managing Alzheimer's disease: Part II. Treatment. <i>American Family Physician</i> , 2002 , 65, 2525-34	1.3	54
51	Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. <i>Movement Disorders</i> , 2001 , 16, 1098-104	7	36
50	Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 789-93	3.9	105
49	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. <i>Annals of Neurology</i> , 2001 , 49, 355-361	9.4	222
48	Geriatric Neuropsychopharmacology: Unmet Needs. <i>Psychogeriatrics</i> , 2001 , 1, 14-26	1.8	
47	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting. <i>Journal of the American Geriatrics Society</i> , 2001 , 49, 1590-1599	5.6	269
46	Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001 , 14, 101-8	3.8	41

45	Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. <i>International Psychogeriatrics</i> , 2001 , 13, 121-8	3.4	100
44	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting 2001 , 49, 1590		5
43	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease 2001 , 49, 355		7
42	Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000 , 12, 209-18	2.7	43
41	Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. <i>Archives of Neurology</i> , 2000 , 57, 861-6		108
40	Utilization of Alzheimer's disease community resources by Asian-Americans in California. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 838-47	3.9	43
39	Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000 , 12, 233-9	2.7	944
38	Functional correlates of musical and visual ability in frontotemporal dementia. <i>British Journal of Psychiatry</i> , 2000 , 176, 458-63	5.4	180
37	Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. <i>Neurobiology of Aging</i> , 2000 , 21, 845-61	5.6	166
36	Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. <i>CNS Drugs</i> , 2000 , 13, 385-395	6.7	11
35	The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. <i>American Journal of Geriatric Psychiatry</i> , 2000 , 8, 75-83	6.5	294
34	Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , 1999 , 2, 59-66	5.8	6
33	The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. <i>Archives of Neurology</i> , 1999 , 56, 1388-93		193
32	Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 463-71	5.9	15
31	Neuropsychiatric aspects of dementia with Lewy bodies. <i>Current Psychiatry Reports</i> , 1999 , 1, 85-92	9.1	18
30	Measuring Outcomes in Alzheimer's Disease Research. <i>Disease Management and Health Outcomes</i> , 1999 , 5, 1-12		5
29	Gender-related cognitive deficits in Alzheimer's disease. <i>International Psychogeriatrics</i> , 1999 , 11, 117-22	3.4	41
28	Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. <i>Neurocase</i> , 1999 , 5, 181-188	0.8	8

27	Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. <i>Neurocase</i> , 1999 , 5, 181-188	0.8	
26	Apathy is not depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998 , 10, 314-9	2.7	437
25	Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. <i>Journal of the American Geriatrics Society</i> , 1998 , 46, 210-5	5.6	383
24	Behavioral disorders in Alzheimer disease: a transcultural perspective. <i>Archives of Neurology</i> , 1998 , 55, 539-44		88
23	Anti-dementia drugs: what difference do they make?. <i>Reviews in Clinical Gerontology</i> , 1998 , 8, 279-280		
22	Treatment of Depression in the Patient with Parkinson's Disease 1998 , 6, 34-46		1
21	Barriers to behavioral research on dementia. <i>International Psychogeriatrics</i> , 1996 , 8 Suppl 1, 21-3	3.4	1
20	Neuropsychiatric assessment and intervention in Alzheimer's disease. <i>International Psychogeriatrics</i> , 1996 , 8 Suppl 1, 25-30	3.4	8
19	Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia. <i>Journal of the International Neuropsychological Society</i> , 1996 , 2, 505-10	3.1	112
18	Quantitative EEG in frontotemporal dementia. <i>Clinical EEG (electroencephalography)</i> , 1996 , 27, 61-8		50
17	The spectrum of behavioral changes in Alzheimer's disease. <i>Neurology</i> , 1996 , 46, 130-5	6.5	863
16	Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996 , 9, 1-6	3.8	129
15	Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression. <i>Neurocase</i> , 1996 , 2, 455-459	0.8	3
14	Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression. <i>Neurocase</i> , 1996 , 2, 455-459	0.8	
13	The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. <i>European Journal of Haematology</i> , 1995 , 54, 245-53	3.8	80
12	Neurobehavioural examination of frontal lobe functions. <i>Aphasiology</i> , 1995 , 9, 181-192	1.6	16
11	Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. <i>American Journal of Geriatric Psychiatry</i> , 1994 , 2, 200-209	6.5	7
10	Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. <i>Journal of the American Geriatrics Society</i> , 1992 , 40, 549-55	5.6	75

9	Behavioral complications of drug treatment of Parkinson's disease. <i>Journal of the American Geriatrics Society</i> , 1991 , 39, 708-16	5.6	119
8	Speech and language alterations in dementia syndromes: Characteristics and treatment. <i>Aphasiology</i> , 1990 , 4, 339-352	1.6	21
7	Psychological dysfunction accompanying subcortical dementias. <i>Annual Review of Medicine</i> , 1988 , 39, 53-61	17.4	72
6	Altered Behavior Associated with Damage to the Ventromedial Hypothalamus: A Distinctive Syndrome. <i>Behavioural Neurology</i> , 1988 , 1, 49-58	3	26
5	Atypical dementia syndrome in an elderly man. <i>Journal of the American Geriatrics Society</i> , 1987 , 35, 1116-26	5.4	3
4	De Clérambault's syndrome in organic affective disorder. Two cases. <i>British Journal of Psychiatry</i> , 1987 , 151, 404-7	5.4	33
3	Treatment of Alzheimer's disease 415-424		
2	Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease		8
1	Clinical Trials in Dementia 1		